Cited by 111Fatty Acid Research and HealthRheumatoid Arthritis Research and TherapiesInflammatory mediators and NSAID effects

Session 3: Joint Nutrition Society and Irish Nutrition and Dietetic Institute Symposium on ‘Nutrition and autoimmune disease’ PUFA, inflammatory processes and rheumatoid arthritis: Symposium on ‘The challenge of translating nutrition research into public health nutrition’

Open access
Calder, Philip C.·2008·Proceedings of The Nutrition Society

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease manifested by swollen and painful joints, bone erosion and functional impairment. The joint lesions are characterised by infiltration of T lymphocytes, macrophages and B lymphocytes into the synovium and by synovial inflammation involving eicosanoids, cytokines and matrix metalloproteinases. In relation to inflammatory processes, the main fatty acids of interest are the n-6 PUFA arachidonic acid, which is the precursor of inflammatory eicosanoids such as PGE2 and leukotriene B4, and the n-3 PUFA EPA and DHA, which are found in oily fish and fish oils. Eicosanoids derived from the n-6 PUFA arachidonic acid play a role in RA, and the efficacy of non-steroidal anti-inflammatory drugs in RA indicates the importance of pro-inflammatory cyclooxygenase pathway products of arachidonic acid in the pathophysiology of the disease. EPA and DHA inhibit arachidonic acid metabolism to inflammatory eicosanoids. EPA also gives rise to eicosanoid mediators that are less inflammatory than those produced from arachidonic acid and both EPA and DHA give rise to resolvins that are anti-inflammatory and inflammation resolving. In addition to modifying the lipid mediator profile, n-3 PUFA exert effects on other aspects of immunity relevant to RA such as antigen presentation, T-cell reactivity and inflammatory cytokine production. Fish oil has been shown to slow the development of arthritis in an animal model and to reduce disease severity. Randomised clinical trials have demonstrated a range of clinical benefits in patients with RA that include reducing pain, duration of morning stiffness and use of non-steroidal anti-inflammatory drugs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0029665108008690

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A combination of L. gasseri CECT5714 and L. coryniformis CECT5711 with Staphylococcus thermophilus for two or four weeks had no effect on serum TNF-α or IL-12 concentrations in healthy adults aged 23-43 years.

    “Likewise, the combination of L. gasseri CECT5714 and L. coryniformis CECT5711 (2 £ 10 9 CFU of each/d) with Staphylococcus thermophilus (10 8 CFU/d) for 2 or 4 weeks had no effect on serum TNF-a or IL-12 concentrations in healthy adults aged 23-43 years (830,831) .”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Calder, P. C.
Affiliations
Southampton General Hospital (GB)
Corresponding author
Calder, Philip C.
Venue
Proceedings of The Nutrition Society
Published
2008-10-10
Volume
67
Issue
4
Pages
409-418
ISSN
  • 0029-6651 (ISSN-L)
  • 1475-2719
OpenAlex
W2157486327
Cited by
111
References
108
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2022: 5 · 2021: 6 · 2020: 4 · 2018: 7 · 2017: 2 · 2016: 9 · 2015: 7 · 2014: 12 · 2013: 10 · 2012: 19
FWCI
0.71
Type
journal article
Language
en
Open access
Locations
  • Proceedings of The Nutrition Society (publishedVersion)
  • PubMed (publishedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion)
Funders
  • Danone
  • Vifor Pharma
  • Danone Research Centre for Specialised Nutrition
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
Keywords
rheumatoid arthritis, polyunsaturated fatty acids, omega-3 fatty acids, eicosanoids, arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, fish oil, resolvins, inflammation, autoimmune disease, cyclooxygenase pathway, nonsteroidal anti-inflammatory drugs, synovitis
MeSH terms
Animals, Anti-Inflammatory Agents, Non-Steroidal, Arthritis, Rheumatoid, Disease Models, Animal, Fish Oils, Humans, Fatty Acids, Omega-3, Eicosanoids, Fatty Acids, Omega-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review